StonvexLoading…
StonvexStonvexStonvexCore line items from CNMD's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $1.37B | $1.31B | $1.24B | $1.05B |
Operating Income | $102.62M | $200.33M | $120.60M | $70.05M |
Net Income | $47.05M | $132.42M | $64.46M | $-80.58M |
EPS (Diluted) | $1.51 | $4.25 | $2.04 | $-2.68 |
Total Assets | $2.33B | $2.31B | $2.30B | $2.30B |
Total Liabilities | $1.29B | $1.34B | $1.47B | $1.55B |
Cash & Equivalents | $40.82M | $24.46M | $24.30M | $28.94M |
Free Cash Flow OCF − CapEx | $150.88M | $153.88M | $106.32M | $11.58M |
Shares Outstanding | 31.15M | 31.15M | 31.55M | 30.04M |